NEW HIGHLIGHT
Sybrava

Sybrava

inclisiran

Manufacturer:

Novartis

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Inclisiran
Indications/Uses
Primary hypercholesterolaemia (heterozygous familial & non-familial) or mixed dyslipidaemia as adjunct to diet in combination w/ statin or statin w/ other lipid-lowering therapies in patients unable to reach LDL-C goals w/ max tolerated dose of statin; or as monotherapy or in combination w/ other lipid-lowering therapies in patients who are statin-intolerant or whom statin is contraindicated.
Dosage/Direction for Use
SC Recommended dose: Initially 284 mg as single SC inj into abdomen, thigh or upper arm. Repeat at 3 mth, followed by every 6 mth.
Contraindications
Special Precautions
Not to be given into areas of active skin disease or injury (eg, sunburns, skin rashes, inflammation or infections). Not to perform haemodialysis for at least 72 hr after treatment. Severe hepatic impairment (Child-Pugh class C). Avoid use during pregnancy. Lactation. Childn <18 yr.
Adverse Reactions
MIMS Class
Dyslipidaemic Agents
ATC Classification
C10AX16 - inclisiran ; Belongs to the class of other lipid modifying agents.
Presentation/Packing
Form
Sybrava soln for inj 284 mg/1.5 mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in